| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.088 | 0.2 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.3 |